-+ 0.00%
-+ 0.00%
-+ 0.00%

Propanc Biopharma plans 2026 Phase 1b first-in-human trial of PRP after 85% tumor inhibition in preclinical pancreatic models

Reuters·03/12/2026 12:45:21

Please log in to view news